Appointment dossier — Endometrioid Carcinoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Endometrioid Carcinoma
- Carboplatin — Human evidence · 0 positive / 1 negative-mixed · PMID 30036218
- Paclitaxel — Human evidence · 0 positive / 1 negative-mixed · PMID 30036218
- Cisplatin — Lab evidence · 0 positive / 1 negative-mixed · PMID 35106124
- Sulfasalazine †Rx — Lab evidence · 0 positive / 1 negative-mixed · PMID 35106124
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT04111978 · Phase 3 — MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (Austria)
- NCT05945407 — Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer (China)
- NCT06466382 — OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy (Switzerland)
- NCT06468215 — Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer (China)
- NCT06549855 — PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer (China)
- NCT04575935 · Phase 3 — Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial (United States)
- NCT05256225 · Phase 3 — Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma (United States)
- NCT06580314 · Phase 3 — Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer (United States)
- NCT05281471 · Phase 3 — Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) (United States)
- NCT03422198 · Phase 3 — Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer (United States)
- NCT06639074 · Phase 2 — Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (United States)
- NCT05112601 · Phase 2 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (United States)
- NCT05920798 · Phase 1 / Phase 2 — Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (United States)
- NCT06690775 · Phase 2 — CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (United States)
- NCT04919629 · Phase 2 — APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion (United States)
- NCT05997017 · Phase 2 — Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer (United States)
- NCT05231122 · Phase 2 — Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer (United States)
- NCT07690189 · Phase 1 — Study of NTB-928 in R/R OC (United States)
Most-relevant first: trials that name Endometrioid Carcinoma, then broader trials you may still qualify for. 29 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Interactions & safety to discuss
Not a complete check — a drug not listed here is not therefore safe. Show your pharmacist your full list.
- Sulfasalazine †Rx × sulfa_allergy_drugs (high-stakes) — Contraindicate (high)
- Sulfasalazine †Rx × folate_antagonists — Monitor (moderate)
- Sulfasalazine †Rx × Cisplatin — Synergize (low)
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- I've read that Carboplatin has been studied in people for Endometrioid Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- I've read that Paclitaxel has been studied in people for Endometrioid Carcinoma — what's the evidence, and is it an option or available in a trial for me?
- Of the open trials I found (for example NCT04111978), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?